Merck's top cancer team basks in the warm light of positive Keytruda data from a landmark study for hard-to-treat breast cancer
BARCELONA — While Bristol-Myers Squibb execs spent much of the weekend in Barcelona trying to explain the more positive aspects of recent data on Opdivo, the dominant development team over at Merck was accepting a fresh round of kudos for another landmark first involving their leading PD-1 Keytruda.
The Merck team was on hand to spotlight a sharp increase in the number of patients who gained a pathological complete response (pCR) for high-risk, early-stage triple negative breast cancer using a neoadjuvant regimen of Keytruda plus chemo followed by adjuvant Keytruda monotherapy — compared to neoadjuvant chemo followed by adjuvant placebo. The researchers scored the data from KEYNOTE-522 at 51.2% for the control arm compared to 64.8% for the Keytruda-plus arm.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.